Cancer Research Cancer Health Disparities Conference 2009 SU2C
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Campbell, I. G.
Right arrow Articles by Phillips, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Campbell, I. G.
Right arrow Articles by Phillips, W. A.
[Cancer Research 64, 7678-7681, November 1, 2004]
© 2004 American Association for Cancer Research

Advances in Brief

Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

Ian G. Campbell1, Sarah E. Russell1,2, David Y. H. Choong1, Karen G. Montgomery1, Marianne L. Ciavarella2, Christine S. F. Hooi1, Briony E. Cristiano3, Richard B. Pearson3 and Wayne A. Phillips2

1 VBCRC Cancer Genetics Laboratory, 2 Surgical Oncology Research Laboratory, and 3 Protein Chemistry Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Phosphatidylinositol 3'-kinases are lipid kinases with important roles in neoplasia. Recently, a very high frequency of somatic mutations in PIK3CA has been reported among a large series of colorectal cancers. However, the relevance of PIK3CA mutation in other cancer types remains unclear because of the limited number of tumors investigated. We have screened a total of 284 primary human tumors for mutations in all coding exons of PIK3CA using a combination of single stranded conformational polymorphism and denaturing high-performance liquid chromatography analysis. Among 70 primary breast cancers, 40% (28 of 70) harbored mutations in PIK3CA, making it the most common mutation described to date in this cancer type. Mutations were not associated with histologic subtype, estrogen receptor status, grade or presence of tumor in lymph nodes. Among the primary epithelial ovarian cancers only 11 of 167 (6.6%) contain somatic mutations, but there was a clear histologic subtype bias in their distribution. Only 2 of 88 (2.3%) of serous carcinomas had PIK3CA mutations compared with 8 of 40 (20.0%) endometrioid and clear cell cancers, which was highly significant (P = 0.001). In contrast, PIK3CA gene amplification (>7-fold) was common among all histologic subtypes (24.5%) and was inversely associated with the presence of mutations. Overall, PIK3CA mutation or gene amplification was detected in 30.5% of all ovarian cancers and 45% of the endometrioid and clear cell subtypes. Our study is the first direct evidence that PIK3CA is an oncogene in ovarian cancer and greatly extends recent findings in breast cancer.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
O. Renner, C. Blanco-Aparicio, M. Grassow, M. Canamero, J. F.M. Leal, and A. Carnero
Activation of Phosphatidylinositol 3-Kinase by Membrane Localization of p110{alpha} Predisposes Mammary Glands to Neoplastic Transformation
Cancer Res., December 1, 2008; 68(23): 9643 - 9653.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Serra, B. Markman, M. Scaltriti, P. J.A. Eichhorn, V. Valero, M. Guzman, M. L. Botero, E. Llonch, F. Atzori, S. Di Cosimo, et al.
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Cancer Res., October 1, 2008; 68(19): 8022 - 8030.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Oda, J. Okada, L. Timmerman, P. Rodriguez-Viciana, D. Stokoe, K. Shoji, Y. Taketani, H. Kuramoto, Z. A. Knight, K. M. Shokat, et al.
PIK3CA Cooperates with Other Phosphatidylinositol 3'-Kinase Pathway Mutations to Effect Oncogenic Transformation
Cancer Res., October 1, 2008; 68(19): 8127 - 8136.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Wee, D. Wiederschain, S.-M. Maira, A. Loo, C. Miller, R. deBeaumont, F. Stegmeier, Y.-M. Yao, and C. Lengauer
PTEN-deficient cancers depend on PIK3CB
PNAS, September 2, 2008; 105(35): 13057 - 13062.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S.-H. Lo, H. Chernoff, L. Cong, Y. Ding, and T. Zheng
Discovering interactions among BRCA1 and other candidate genes associated with sporadic breast cancer
PNAS, August 26, 2008; 105(34): 12387 - 12392.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. B. Kaye
Reversal of Drug Resistance in Ovarian Cancer: Where Do We Go From Here?
J. Clin. Oncol., June 1, 2008; 26(16): 2616 - 2618.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
Y.-L. Lai, B.-L. Mau, W.-H. Cheng, H.-M. Chen, H.-H. Chiu, and C.-Y. Tzen
PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients
Ann. Surg. Oncol., April 1, 2008; 15(4): 1064 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. E. Board, N. J. Thelwell, P. F. Ravetto, S. Little, M. Ranson, C. Dive, A. Hughes, and D. Whitcombe
Multiplexed Assays for Detection of Mutations in PIK3CA
Clin. Chem., April 1, 2008; 54(4): 757 - 760.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Zhao and P. K. Vogt
Helical domain and kinase domain mutations in p110{alpha} of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
PNAS, February 19, 2008; 105(7): 2652 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
C.-H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, S. B. Gabelli, and L. M. Amzel
The Structure of a Human p110{alpha}/p85{alpha} Complex Elucidates the Effects of Oncogenic PI3K{alpha} Mutations
Science, December 14, 2007; 318(5857): 1744 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Barbareschi, F. Buttitta, L. Felicioni, S. Cotrupi, F. Barassi, M. Del Grammastro, A. Ferro, P. Dalla Palma, E. Galligioni, and A. Marchetti
Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas
Clin. Cancer Res., October 15, 2007; 13(20): 6064 - 6069.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Zhang, J. Huang, N. Yang, J. Greshock, S. Liang, K. Hasegawa, A. Giannakakis, N. Poulos, A. O'Brien-Jenkins, D. Katsaros, et al.
Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer
Clin. Cancer Res., September 15, 2007; 13(18): 5314 - 5321.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. L. Howes, G. G. Chiang, E. S. Lang, C. B. Ho, G. Powis, K. Vuori, and R. T. Abraham
The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures
Mol. Cancer Ther., September 1, 2007; 6(9): 2505 - 2514.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. Blanco-Aparicio, O. Renner, J. F.M. Leal, and A. Carnero
PTEN, more than the AKT pathway
Carcinogenesis, July 1, 2007; 28(7): 1379 - 1386.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
O. Renner, J. Fominaya, S. Alonso, C. Blanco-Aparicio, J. F.M. Leal, and A. Carnero
Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate
Carcinogenesis, July 1, 2007; 28(7): 1418 - 1425.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Perez-Tenorio, L. Alkhori, B. Olsson, M. A. Waltersson, B. Nordenskjold, L. E. Rutqvist, L. Skoog, and O. Stal
PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer
Clin. Cancer Res., June 15, 2007; 13(12): 3577 - 3584.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Nanjundan, Y. Nakayama, K. W. Cheng, J. Lahad, J. Liu, K. Lu, W.-L. Kuo, K. Smith-McCune, D. Fishman, J. W. Gray, et al.
Amplification of MDS1/EVI1 and EVI1, Located in the 3q26.2 Amplicon, Is Associated with Favorable Patient Prognosis in Ovarian Cancer
Cancer Res., April 1, 2007; 67(7): 3074 - 3084.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Gymnopoulos, M.-A. Elsliger, and P. K. Vogt
Rare cancer-specific mutations in PIK3CA show gain of function
PNAS, March 27, 2007; 104(13): 5569 - 5574.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Wang, K. Kuropatwinski, J. Hauser, M. R. Rossi, Y. Zhou, A. Conway, J. L.C. Kan, N. W. Gibson, J. K.V. Willson, J. K. Cowell, et al.
Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis
Mol. Cancer Ther., March 1, 2007; 6(3): 1143 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Hou, D. Liu, Y. Shan, S. Hu, K. Studeman, S. Condouris, Y. Wang, A. Trink, A. K. El-Naggar, G. Tallini, et al.
Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1161 - 1170.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Maruyama, Y. Miyoshi, T. Taguchi, Y. Tamaki, M. Monden, and S. Noguchi
Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women
Clin. Cancer Res., January 15, 2007; 13(2): 408 - 414.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. E. Cristiano, J. C. Chan, K. M. Hannan, N. A. Lundie, N. J. Marmy-Conus, I. G. Campbell, W. A. Phillips, M. Robbie, R. D. Hannan, and R. B. Pearson
A Specific Role for AKT3 in the Genesis of Ovarian Cancer through Modulation of G2-M Phase Transition
Cancer Res., December 15, 2006; 66(24): 11718 - 11725.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. P. Hayes, H. Wang, R. Espinal-Witter, W. Douglas, G. J. Solomon, S. J. Baker, and L. H. Ellenson
PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia.
Clin. Cancer Res., October 15, 2006; 12(20): 5932 - 5935.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
G. L. Gallia, V. Rand, I-M. Siu, C. G. Eberhart, C. D. James, S. K.N. Marie, S. M. Oba-Shinjo, C. G. Carlotti, O. L. Caballero, A. J.G. Simpson, et al.
PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme
Mol. Cancer Res., October 1, 2006; 4(10): 709 - 714.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. W. Watters and C. J. Roberts
Developing gene expression signatures of pathway deregulation in tumors.
Mol. Cancer Ther., October 1, 2006; 5(10): 2444 - 2449.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Y. C. Antill, G. Mitchell, S. A. Johnson, L. Devereux, A. Milner, K.-A. Phillips, and I. G. Campbell
Loss of Heterozygosity Analysis in Ductal Lavage Samples from BRCA1 and BRCA2 Carriers: A Cautionary Tale.
Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1396 - 1398.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
T. R. Pettitt, S. K. Dove, A. Lubben, S. D. J. Calaminus, and M. J. O. Wakelam
Analysis of intact phosphoinositides in biological samples
J. Lipid Res., July 1, 2006; 47(7): 1588 - 1596.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
N. Pore, Z. Jiang, H.-K. Shu, E. Bernhard, G. D. Kao, and A. Maity
Akt1 Activation Can Augment Hypoxia-Inducible Factor-1{alpha} Expression by Increasing Protein Translation through a Mammalian Target of Rapamycin-Independent Pathway
Mol. Cancer Res., July 1, 2006; 4(7): 471 - 479.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. G. Campbell, W. A. Phillips, and D. Y.H. Choong
Genetic and Epigenetic Analysis of the Putative Tumor Suppressor km23 in Primary Ovarian, Breast, and Colorectal Cancers.
Clin. Cancer Res., June 15, 2006; 12(12): 3713 - 3715.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Schonleben, W. Qiu, N. T. Ciau, D. J. Ho, X. Li, J. D. Allendorf, H. E. Remotti, and G. H. Su
PIK3CA Mutations in Intraductal Papillary Mucinous Neoplasm/Carcinoma of the Pancreas.
Clin. Cancer Res., June 15, 2006; 12(12): 3851 - 3855.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Yao, S. Weremowicz, B. Feng, R. C. Gentleman, J. R. Marks, R. Gelman, C. Brennan, and K. Polyak
Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression.
Cancer Res., April 15, 2006; 66(8): 4065 - 4078.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. L. Janmaat, M. I. Gallegos-Ruiz, J. A. Rodriguez, G. A. Meijer, W. L. Vervenne, D. J. Richel, C. Van Groeningen, and G. Giaccone
Predictive Factors for Outcome in a Phase II Study of Gefitinib in Second-Line Treatment of Advanced Esophageal Cancer Patients
J. Clin. Oncol., April 1, 2006; 24(10): 1612 - 1619.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Qiu, F. Schonleben, X. Li, D. J. Ho, L. G. Close, S. Manolidis, B. P. Bennett, and G. H. Su
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., March 1, 2006; 12(5): 1441 - 1446.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
V. Jung, R. Kindich, J. Kamradt, M. Jung, M. Muller, W. A. Schulz, R. Engers, G. Unteregger, M. Stockle, R. Zimmermann, et al.
Genomic and Expression Analysis of the 3q25-q26 Amplification Unit Reveals TLOC1/SEC62 as a Probable Target Gene in Prostate Cancer
Mol. Cancer Res., March 1, 2006; 4(3): 169 - 176.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
F. Moll, C. Millet, D. Noel, B. Orsetti, A. Bardin, D. Katsaros, C. Jorgensen, M. Garcia, C. Theillet, P. Pujol, et al.
Chordin is underexpressed in ovarian tumors and reduces tumor cell motility
FASEB J, February 1, 2006; 20(2): 240 - 250.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Moscova, D. J. Marsh, and R. C. Baxter
Protein Chip Discovery of Secreted Proteins Regulated by the Phosphatidylinositol 3-Kinase Pathway in Ovarian Cancer Cell Lines
Cancer Res., February 1, 2006; 66(3): 1376 - 1383.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis
Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway
Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H.-J. Kim, X. Cui, S. G. Hilsenbeck, and A. V. Lee
Progesterone Receptor Loss Correlates with Human Epidermal Growth Factor Receptor 2 Overexpression in Estrogen Receptor-Positive Breast Cancer
Clin. Cancer Res., February 1, 2006; 12(3): 1013s - 1018s.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. G. Bader, S. Kang, and P. K. Vogt
Cancer-specific mutations in PIK3CA are oncogenic in vivo
PNAS, January 31, 2006; 103(5): 1475 - 1479.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Beloueche-Babari, L. E. Jackson, N. M.S. Al-Saffar, S. A. Eccles, F. I. Raynaud, P. Workman, M. O. Leach, and S. M. Ronen
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells
Mol. Cancer Ther., January 1, 2006; 5(1): 187 - 196.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. J. Zhao, Z. Liu, L. Wang, E. Shin, M. F. Loda, and T. M. Roberts
The oncogenic properties of mutant p110{alpha} and p110{beta} phosphatidylinositol 3-kinases in human mammary epithelial cells
PNAS, December 20, 2005; 102(51): 18443 - 18448.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Oda, D. Stokoe, Y. Taketani, and F. McCormick
High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma
Cancer Res., December 1, 2005; 65(23): 10669 - 10673.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. J. Isakoff, J. A. Engelman, H. Y. Irie, J. Luo, S. M. Brachmann, R. V. Pearline, L. C. Cantley, and J. S. Brugge
Breast Cancer-Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
Cancer Res., December 1, 2005; 65(23): 10992 - 11000.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Garcia-Rostan, A. M. Costa, I. Pereira-Castro, G. Salvatore, R. Hernandez, M. J.A. Hermsem, A. Herrero, A. Fusco, J. Cameselle-Teijeiro, and M. Santoro
Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer
Cancer Res., November 15, 2005; 65(22): 10199 - 10207.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. G. Campbell, S. E. Russell, W. A. Phillips, D. A. Levine, and J. Boyd
PIK3CA Mutations in Ovarian Cancer
Clin. Cancer Res., October 1, 2005; 11(19): 7042 - 7043.
[Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
T Frogne, J S Jepsen, S S Larsen, C K Fog, B L Brockdorff, and A E Lykkesfeldt
Antiestrogen-resistant human breast cancer cells require activated Protein Kinase B/Akt for growth
Endocr. Relat. Cancer, September 1, 2005; 12(3): 599 - 614.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Luo, C. L. Sobkiw, N. M. Logsdon, J. M. Watt, S. Signoretti, F. O'Connell, E. Shin, Y. Shim, L. Pao, B. G. Neel, et al.
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase
PNAS, July 19, 2005; 102(29): 10238 - 10243.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Ikenoue, F. Kanai, Y. Hikiba, T. Obata, Y. Tanaka, J. Imamura, M. Ohta, A. Jazag, B. Guleng, K. Tateishi, et al.
Functional Analysis of PIK3CA Gene Mutations in Human Colorectal Cancer
Cancer Res., June 1, 2005; 65(11): 4562 - 4567.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. A. Levine, F. Bogomolniy, C. J. Yee, A. Lash, R. R. Barakat, P. I. Borgen, and J. Boyd
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Clin. Cancer Res., April 15, 2005; 11(8): 2875 - 2878.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga and C. L. Arteaga
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
J. Clin. Oncol., April 10, 2005; 23(11): 2445 - 2459.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. W. Cheng, J. P. Lahad, J. W. Gray, and G. B. Mills
Emerging Role of RAB GTPases in Cancer and Human Disease
Cancer Res., April 1, 2005; 65(7): 2516 - 2519.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. H. Saal, K. Holm, M. Maurer, L. Memeo, T. Su, X. Wang, J. S. Yu, P.-O. Malmstrom, M. Mansukhani, J. Enoksson, et al.
PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma
Cancer Res., April 1, 2005; 65(7): 2554 - 2559.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Shin, J. Edl, S. Biswas, P. C. Lin, R. Mernaugh, and C. L. Arteaga
Proapoptotic Activity of Cell-Permeable Anti-Akt Single-Chain Antibodies
Cancer Res., April 1, 2005; 65(7): 2815 - 2824.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
M. D. Pegram
Molecular Determinants of Trastuzumab Response/Resistance
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 155 - 159.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.